


Top 25 Drugs

Top 25 drugs in 2016 by total expenditures in all sectors.




- Increases
 - RA/UC/CD therapies
 - Nivolumab
 - Insulin products
- Decreases
 - Hepatitis C therapies
- Generic Approvals
 - Rosuvastatin

Schumock GT, Li EC, Wiest MD, et al. *Am J Health Syst Pharm.* 2017 Aug 1;74(15):1158-1173.

Top 25 Drugs

Top 25 drugs in 2016 by expenditures in clinics.




- Infliximab is consistently the top spend in clinics since 2013
 - Biosimilar not yet launched until late 2016
- Immuno-oncology therapies: nivolumab, pembrolizumab, ipilimumab

Schumock GT, Li EC, Wiest MD, et al. *Am J Health Syst Pharm.* 2017 Aug 1;74(15):1158-1173.

The Biosimilars Story in Oncology

Figure 3. Comparison of Spending on Traditional Drugs, Older Biologics and Newer Biologics



Li EC, Schumock G, Hong S. Spending on antineoplastic agents in the United States: 2011-2016. *Journal of Clinical Oncology* 35, no. 15_suppl (May 2017) 6618-6618. 2017 American Society of Clinical Oncology Annual Meeting; Chicago, IL. June 5, 2017.